Premium
High‐dose, short‐duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer
Author(s) -
Hunter Richard E.,
Griffin Thomas W.,
Stevens Sarah,
Roman Lynda D.,
Bokhari Faran,
Reale Frank R.,
Tak Won K.,
Fitzgerald T. J.,
Dillon Michael B.,
Rose Peter G.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19911101)68:9<1890::aid-cncr2820680907>3.0.co;2-t
Subject(s) - medicine , chemotherapy , cisplatin , cyclophosphamide , laparotomy , ovarian cancer , doxorubicin , surgery , radiation therapy , gastroenterology , urology , cancer , oncology
Sixty‐one patients with epithelial ovarian cancer were treated with intensive high‐dose, short‐course chemotherapy that consisted of cisplatin (120 mg/m 2 ) and doxorubicin (70 mg/m 2 ) every 3 weeks for four cycles. Patients in complete clinical remission were offered second‐look laparotomy (SLL). Patients with minimal or no residual disease at SLL were randomized to either cyclophosphamide (1000 mg/m 2 every 21 days for six cycles) or whole‐abdominal radiation therapy. All patients completed therapy with a median leukocyte nadir 1.3/μl and platelet nadir of 90/μl. Forty‐five patients (74%) had a complete clinical response. Results of twenty‐two of 36 second‐look procedures (64%) showed no evidence of disease (NED). After SLL, 19 patients received six courses of cyclophosphamide and 16 patients received whole‐abdominal radiation. Nine patient who refused SLL and one patient with negative SLL findings refused additional treatment. The median survival time for all patients was 51.3 months. High‐dose intensive chemotherapy regimens have high response rates, but survival needs to be compared with traditional low‐dose regimens. Although high‐dose cisplatin and doxorubicin were myelosuppressive, the resulting complications were manageable. There was no significant difference between the mean survival times of patients receiving Cytoxan, abdominal radiation, or no treatment as second‐line therapy.